Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 419

1.

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN.

Gynecol Oncol. 2020 Feb 18. pii: S0090-8258(20)30090-1. doi: 10.1016/j.ygyno.2020.01.037. [Epub ahead of print]

PMID:
32081463
2.

Low-grade serous ovarian cancer: State of the science.

Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM.

Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(19)31862-1. doi: 10.1016/j.ygyno.2019.12.033. [Epub ahead of print] Review.

PMID:
31969252
3.

Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.

Bixel K, Vetter M, Davidson B, Berchuck A, Cohn D, Copeland L, Fowler JM, Havrilesky L, Lee PS, O'Malley DM, Salani R, Valea F, Alvarez Secord A, Backes F.

Gynecol Oncol. 2020 Jan 11. pii: S0090-8258(19)31837-2. doi: 10.1016/j.ygyno.2019.12.016. [Epub ahead of print]

PMID:
31937450
4.

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.

Alvarez Secord A, Bell Burdett K, Owzar K, Tritchler D, Sibley AB, Liu Y, Starr MD, Brady JC, Lankes HA, Hurwitz HI, Mannel RS, Tewari KS, O'Malley DM, Gray H, Bakkum-Gamez JN, Fujiwara K, Boente M, Deng W, Burger RA, Birrer MJ, Nixon AB.

Clin Cancer Res. 2020 Jan 9. doi: 10.1158/1078-0432.CCR-19-0226. [Epub ahead of print]

PMID:
31919136
5.

EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.

Arend RC, Davis AM, Chimiczewski P, O'Malley DM, Provencher D, Vergote I, Ghamande S, Birrer MJ.

Gynecol Oncol. 2020 Feb;156(2):301-307. doi: 10.1016/j.ygyno.2019.12.002. Epub 2019 Dec 20.

PMID:
31870556
6.

EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas.

Maracaja DLV, Puthenpura V, Pels SG, O'Malley DP, Sklar JL, Finberg KE, Xu ML.

Appl Immunohistochem Mol Morphol. 2019 Nov 26. doi: 10.1097/PAI.0000000000000820. [Epub ahead of print]

PMID:
31789821
7.

Understanding primary care-oncology relationships within a changing healthcare environment.

Tsui J, Howard J, O'Malley D, Miller WL, Hudson SV, Rubinstein EB, Ferrante JM, Bator A, Crabtree BF.

BMC Fam Pract. 2019 Nov 28;20(1):164. doi: 10.1186/s12875-019-1056-y.

8.

The life and death of the germinal center.

Gars E, Butzmann A, Ohgami R, Balakrishna JP, O'Malley DP.

Ann Diagn Pathol. 2020 Feb;44:151421. doi: 10.1016/j.anndiagpath.2019.151421. Epub 2019 Nov 13. Review.

PMID:
31751845
9.

A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.

Moore KN, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, O'Cearbhaill RE, Guntupalli SR, Armstrong DK, Hagemann AR, Gray HJ, Duska LR, Mathews CA, Chen A, O'Malley D, Gordon S, Fracasso PM, Aghajanian C.

Gynecol Oncol. 2020 Jan;156(1):13-22. doi: 10.1016/j.ygyno.2019.10.012. Epub 2019 Nov 7.

PMID:
31708167
10.

Development and usability testing of the e-EXCELS tool to guide cancer survivorship follow-up care.

O'Malley DM, Davis SN, Devine KA, Sullivan B, Bator A, Clemow L, Ferrante JM, Findley PA, Miller SM, Hudson SV.

Psychooncology. 2020 Jan;29(1):123-131. doi: 10.1002/pon.5222. Epub 2019 Oct 18.

PMID:
31626397
11.

Discovery of Pyridazinone and Pyrazolo[1,5-a]pyridine Inhibitors of C-Terminal Src Kinase.

O'Malley DP, Ahuja V, Fink B, Cao C, Wang C, Swanson J, Wee S, Gavai AV, Tokarski J, Critton D, Paiva AA, Johnson BM, Szapiel N, Xie D.

ACS Med Chem Lett. 2019 Sep 25;10(10):1486-1491. doi: 10.1021/acsmedchemlett.9b00354. eCollection 2019 Oct 10.

PMID:
31620238
12.

The Glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of Irritable Bowel Syndrome.

O'Brien R, O'Malley D.

Neurogastroenterol Motil. 2020 Feb;32(2):e13738. doi: 10.1111/nmo.13738. Epub 2019 Oct 11.

PMID:
31602785
13.

Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis.

Xu ML, Gabali A, Hsi ED, Fedoriw Y, Vij K, Salama ME, Ramchandren R, O'Malley D, Wick MR, Battistella M, Gru AA.

Am J Surg Pathol. 2020 Feb;44(2):e1-e14. doi: 10.1097/PAS.0000000000001368.

PMID:
31567279
14.

Rosai-Dorfman Disease of the Breast With Variable IgG4+ Plasma Cells: A Diagnostic Mimicker of Other Malignant and Reactive Entities.

Hoffmann JC, Lin CY, Bhattacharyya S, Weinberg OK, Chisholm KM, Bayerl M, Cascio M, Venkataraman G, Allison K, Troxell M, Chang CC, Bagg A, George TI, O'Malley D, Ohgami RS.

Am J Surg Pathol. 2019 Dec;43(12):1653-1660. doi: 10.1097/PAS.0000000000001347.

PMID:
31436555
15.

Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia.

Vetter MH, Smith B, Benedict J, Hade EM, Bixel K, Copeland LJ, Cohn DE, Fowler JM, O'Malley D, Salani R, Backes FJ.

Am J Obstet Gynecol. 2020 Jan;222(1):60.e1-60.e7. doi: 10.1016/j.ajog.2019.08.002. Epub 2019 Aug 8.

PMID:
31401259
16.

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.

Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM.

J Natl Compr Canc Netw. 2019 Aug 1;17(8):896-909. doi: 10.6004/jnccn.2019.0039.

PMID:
31390583
17.

How much do preclinical medical students utilize the internet to study physiology?

O'Malley D, Barry DS, Rae MG.

Adv Physiol Educ. 2019 Sep 1;43(3):383-391. doi: 10.1152/advan.00070.2019.

18.

Predictive Markers Require Thorough Analytic Validation.

Troxell ML, Fulton RS, Swanson PE, Bellizzi AM, Fitzgibbons PL, Ambaye AB, Haas TS, Goldsmith JD, Loykasek PA, Miller DV, O'Malley D, Qiu J, Salama ME, Schaberg KB, Schwartz RA, Shia J, Summers TA Jr, Wu Y.

Arch Pathol Lab Med. 2019 Aug;143(8):907-909. doi: 10.5858/arpa.2019-0112-LE. No abstract available.

PMID:
31339757
19.

GHSR-1 agonist sensitizes rat colonic intrinsic and extrinsic neurons to exendin-4: A role in the manifestation of postprandial gastrointestinal symptoms in irritable bowel syndrome?

Buckley MM, O'Brien R, Buckley JM, O'Malley D.

Neurogastroenterol Motil. 2019 Oct;31(10):e13684. doi: 10.1111/nmo.13684. Epub 2019 Jul 16.

PMID:
31311066
20.

Bacterial modulation of visceral sensation: mediators and mechanisms.

Lomax AE, Pradhananga S, Sessenwein JL, O'Malley D.

Am J Physiol Gastrointest Liver Physiol. 2019 Sep 1;317(3):G363-G372. doi: 10.1152/ajpgi.00052.2019. Epub 2019 Jul 10.

PMID:
31290688
21.

Women's solutioning and strategising in relation to their postpartum sexual health: A qualitative study.

O'Malley D, Smith V, Higgins A.

Midwifery. 2019 Oct;77:53-59. doi: 10.1016/j.midw.2019.06.012. Epub 2019 Jun 21. No abstract available.

PMID:
31255909
22.

Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx.

Chen PH, Yang Y, O'Malley DP, Xu ML.

Ann Diagn Pathol. 2019 Aug;41:129-135. doi: 10.1016/j.anndiagpath.2019.06.007. Epub 2019 Jun 17.

PMID:
31247533
23.

Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739).

Backes FJ, Cohen D, Salani R, Cohn DE, O'Malley DM, Fanning E, Suarez AA, Fowler JM.

Gynecol Oncol. 2019 Jun;153(3):496-499. doi: 10.1016/j.ygyno.2019.03.252. Epub 2019 Apr 4.

PMID:
31230614
24.

Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.

Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, Griggs JJ, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland J, O'Malley DM, Wright AA.

Am J Obstet Gynecol. 2019 Dec;221(6):625.e1-625.e14. doi: 10.1016/j.ajog.2019.06.009. Epub 2019 Jun 14.

PMID:
31207237
25.

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.

Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, Moxley KM, Kim YM, Powell MA, O'Malley DM, Spirtos NM, Small W Jr, Tewari KS, Richards WE, Nakayama J, Matulonis UA, Huang HQ, Miller DS.

N Engl J Med. 2019 Jun 13;380(24):2317-2326. doi: 10.1056/NEJMoa1813181.

26.

PI 3-kinase- and ERK-MAPK-dependent mechanisms underlie Glucagon-Like Peptide-1-mediated activation of Sprague Dawley colonic myenteric neurons.

O'Brien R, Buckley MM, Kelliher A, O'Malley D.

Neurogastroenterol Motil. 2019 Aug;31(8):e13631. doi: 10.1111/nmo.13631. Epub 2019 May 23.

PMID:
31121089
27.

New Therapies for Ovarian Cancer.

O'Malley DM.

J Natl Compr Canc Netw. 2019 May 1;17(5.5):619-621. doi: 10.6004/jnccn.2019.5018.

PMID:
31117037
28.

Heparan sulphate and hyaluronic acid components of the glycocalyx do not play a role in flow-mediated dilation of the iliac in the anaesthetized pig.

Ruane-O'Hora T, O'Malley D, Buckley MM, Markos F.

Can J Physiol Pharmacol. 2019 Aug;97(8):746-752. doi: 10.1139/cjpp-2019-0124. Epub 2019 May 14.

PMID:
31084580
29.

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.

Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators.

Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.

PMID:
31076365
30.

Rationale and design of extended cancer education for longer term survivors (EXCELS): a randomized control trial of 'high touch' vs. 'high tech' cancer survivorship self-management tools in primary care.

Davis SN, O'Malley DM, Bator A, Ohman-Strickland P, Clemow L, Ferrante JM, Crabtree BF, Miller SM, Findley P, Hudson SV.

BMC Cancer. 2019 Apr 11;19(1):340. doi: 10.1186/s12885-019-5531-6.

31.

Practical Applications in Immunohistochemistry: An Immunophenotypic Approach to the Spleen.

Borch WR, Aguilera NS, Brissette MD, O'Malley DP, Auerbach A.

Arch Pathol Lab Med. 2019 Sep;143(9):1093-1105. doi: 10.5858/arpa.2018-0211-CP. Epub 2019 Mar 27.

PMID:
30917045
32.

A Rare Case of Atypical Placental Site Nodule With an Emerging Intermediate Trophoblastic Tumor.

Dholakia J, Chen W, O'Malley DM, Ronnett BM.

Int J Gynecol Pathol. 2019 Mar 1. doi: 10.1097/PGP.0000000000000598. [Epub ahead of print]

PMID:
30829757
33.

American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.

O'Malley DP, Dogan A, Fedoriw Y, Medeiros LJ, Ok CY, Salama ME.

Ann Diagn Pathol. 2019 Apr;39:105-110. doi: 10.1016/j.anndiagpath.2019.02.001. Epub 2019 Feb 6.

PMID:
30802809
34.

Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases.

O'Malley DP, Yang Y, Boisot S, Sudarsanam S, Wang JF, Chizhevsky V, Zhao G, Arain S, Weiss LM.

Mod Pathol. 2019 Jul;32(7):929-942. doi: 10.1038/s41379-019-0210-3. Epub 2019 Feb 13.

35.

Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer.

Hutchcraft ML, Smith B, McLaughlin EM, Hade EM, Backes FJ, O'Malley DM, Cohn DE, Fowler JM, Copeland LJ, Salani R.

Gynecol Oncol. 2019 May;153(2):255-258. doi: 10.1016/j.ygyno.2019.01.026. Epub 2019 Feb 2.

PMID:
30718123
36.

Nonnegative/Binary matrix factorization with a D-Wave quantum annealer.

O'Malley D, Vesselinov VV, Alexandrov BS, Alexandrov LB.

PLoS One. 2018 Dec 10;13(12):e0206653. doi: 10.1371/journal.pone.0206653. eCollection 2018.

37.

Nonnegative tensor factorization for contaminant source identification.

Vesselinov VV, Alexandrov BS, O'Malley D.

J Contam Hydrol. 2019 Jan;220:66-97. doi: 10.1016/j.jconhyd.2018.11.010. Epub 2018 Dec 4.

PMID:
30528243
38.

Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.

Vetter MH, Khan A, Backes FJ, Bixel K, Cohn DE, Copeland LJ, Fowler JM, Salani R, Li Q, O'Malley DM.

Gynecol Oncol. 2019 Feb;152(2):316-321. doi: 10.1016/j.ygyno.2018.10.037. Epub 2018 Nov 29.

PMID:
30503265
39.

How safe is rucaparib in ovarian cancer?

Cosgrove CM, O'Malley DM.

Expert Opin Drug Saf. 2018 Dec;17(12):1249-1255. doi: 10.1080/14740338.2018.1550067. Epub 2018 Dec 11. Review.

PMID:
30449210
40.

Endocrine regulation of gut function - a role for glucagon-like peptide-1 in the pathophysiology of irritable bowel syndrome.

O'Malley D.

Exp Physiol. 2019 Jan;104(1):3-10. doi: 10.1113/EP087443. Epub 2018 Dec 10. Review.

PMID:
30444291
41.

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM.

Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13.

42.

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.

Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, Gilbert L, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK.

Clin Cancer Res. 2019 Mar 15;25(6):1727-1736. doi: 10.1158/1078-0432.CCR-18-2474. Epub 2018 Nov 9.

PMID:
30413525
43.

Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues.

Grimm KE, O'Malley DP.

Ann Diagn Pathol. 2019 Feb;38:6-10. doi: 10.1016/j.anndiagpath.2018.09.014. Epub 2018 Oct 2. Review.

PMID:
30380402
44.

Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA.

Gynecol Oncol. 2019 Jan;152(1):220. doi: 10.1016/j.ygyno.2018.10.022. Epub 2018 Oct 23. No abstract available.

45.

Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms.

Choi SM, O'Malley DP.

Ann Diagn Pathol. 2018 Dec;37:67-74. doi: 10.1016/j.anndiagpath.2018.09.011. Epub 2018 Sep 27. Review.

PMID:
30308438
46.

Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.

Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O'Malley DM, Robison K, Miller DS.

J Clin Oncol. 2018 Oct 5:JCO1800454. doi: 10.1200/JCO.18.00454. [Epub ahead of print]

47.

Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.

ElNaggar AC, Hade EM, O'Malley DM, Liang MI, Copeland LJ, Fowler JM, Salani R, Backes FJ, Cohn DE.

Gynecol Oncol. 2018 Dec;151(3):501-505. doi: 10.1016/j.ygyno.2018.09.014. Epub 2018 Sep 30.

PMID:
30282591
48.

Recovery of respiratory function in mdx mice co-treated with neutralizing interleukin-6 receptor antibodies and urocortin-2.

Burns DP, Canavan L, Rowland J, O'Flaherty R, Brannock M, Drummond SE, O'Malley D, Edge D, O'Halloran KD.

J Physiol. 2018 Nov;596(21):5175-5197. doi: 10.1113/JP276954. Epub 2018 Oct 3.

49.

Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA.

Gynecol Oncol. 2018 Oct;151(1):18-23. doi: 10.1016/j.ygyno.2018.07.021. Epub 2018 Aug 19. Erratum in: Gynecol Oncol. 2018 Oct 22;:.

50.

Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis.

Billingsley CC, Cohn DE, Crim AK, Li Q, O'Malley DM, Havrilesky LJ.

Cancer Treat Res Commun. 2018;14:21-25. doi: 10.1016/j.ctarc.2017.11.003. Epub 2017 Nov 10.

PMID:
30104004

Supplemental Content

Loading ...
Support Center